IN VITRO EVALUATION OF THIOREDOXIN REDUCTASE INHIBITOR (AURANOFIN) ACTIVITY IN COMPARISON WITH TRICLABENDAZOLE ON ADULT FASCIOLA GIGANTICA
RADY, A., NASSEF, N., EL-SHAFEY, O., BESHAY, E., MAHMOUD, S., ABOUGALALAH, D., EL- REFAI, S. (2021). IN VITRO EVALUATION OF THIOREDOXIN REDUCTASE INHIBITOR (AURANOFIN) ACTIVITY IN COMPARISON WITH TRICLABENDAZOLE ON ADULT FASCIOLA GIGANTICA. EKB Journal Management System, 51(1), 213-226. doi: 10.21608/jesp.2021.165969
AMANY A. RADY; NASHAAT E. NASSEF; OMAIMA K. EL-SHAFEY; ENGY V. BESHAY; SHEREEN F. MAHMOUD; DOAA I. M. ABOUGALALAH; SAMAR A. EL- REFAI. "IN VITRO EVALUATION OF THIOREDOXIN REDUCTASE INHIBITOR (AURANOFIN) ACTIVITY IN COMPARISON WITH TRICLABENDAZOLE ON ADULT FASCIOLA GIGANTICA". EKB Journal Management System, 51, 1, 2021, 213-226. doi: 10.21608/jesp.2021.165969
RADY, A., NASSEF, N., EL-SHAFEY, O., BESHAY, E., MAHMOUD, S., ABOUGALALAH, D., EL- REFAI, S. (2021). 'IN VITRO EVALUATION OF THIOREDOXIN REDUCTASE INHIBITOR (AURANOFIN) ACTIVITY IN COMPARISON WITH TRICLABENDAZOLE ON ADULT FASCIOLA GIGANTICA', EKB Journal Management System, 51(1), pp. 213-226. doi: 10.21608/jesp.2021.165969
RADY, A., NASSEF, N., EL-SHAFEY, O., BESHAY, E., MAHMOUD, S., ABOUGALALAH, D., EL- REFAI, S. IN VITRO EVALUATION OF THIOREDOXIN REDUCTASE INHIBITOR (AURANOFIN) ACTIVITY IN COMPARISON WITH TRICLABENDAZOLE ON ADULT FASCIOLA GIGANTICA. EKB Journal Management System, 2021; 51(1): 213-226. doi: 10.21608/jesp.2021.165969

IN VITRO EVALUATION OF THIOREDOXIN REDUCTASE INHIBITOR (AURANOFIN) ACTIVITY IN COMPARISON WITH TRICLABENDAZOLE ON ADULT FASCIOLA GIGANTICA

Journal of the Egyptian Society of Parasitology
Article 27, Volume 51, Issue 1, April 2021, Page 213-226  XML PDF (676.41 K)
Document Type: Original Article
DOI: 10.21608/jesp.2021.165969
View on SCiNiTO View on SCiNiTO
Authors
AMANY A. RADY1; NASHAAT E. NASSEF1; OMAIMA K. EL-SHAFEY1; ENGY V. BESHAY1; SHEREEN F. MAHMOUD2; DOAA I. M. ABOUGALALAH1; SAMAR A. EL- REFAI1
1Departments of Medical Parasitology
2Departments of Medical Pathology
Abstract
Fasciola gigantica causes a worldwide waterborne/foodborne zoonotic disease in which humans
are incidental hosts. Fascioliasis has a major impact on human health and its control
mainly depends on triclabendazole (TCBZ). Unfortunately, the effectiveness of this drug is
decreased because of indiscriminate use resulting in development of resistance. Therefore, the
search for another effective anthelmintic is now compulsory. This work aimed to evaluate
the in vitro anthelmintic effects of auranofin (a thioredoxin reductase inhibitor) on adult F. gigantica
in comparison with the drug of choice; TCBZ. This study involved in vitro petri dish
incubation of seventy-five adult F. gigantica worms of nearly equal size with the tested drugs
and classified into five groups (fifteen worms each) as follows; G1 served as a control group,
subjected to motility and egg hatchability assays, histopathological and ultrastructural studies,
glutathione-S-transferase and superoxide dismutase assay, and cathepsin-L gene expression
analysis. Auranofin in all concentrations significantly decreased adult motility and egg hatchability.
It induced histopathological and ultrastructural deformities including apoptosis. Auranofin
in higher concentrations significantly suppressed the activity of the detoxifying enzyme;
glutathione-S-transferase, and significantly stimulated superoxide dismutase enzyme activity
reflecting the oxidative stress. At all concentrations, it suppressed the expression of the cathepsin-
L gene responsible for Fasciola invasive function.
Keywords
Auranofin®, Fasciola gigantica; In-vitro, Triclabendazole®
Statistics
Article View: 161
PDF Download: 315